How have AZN shares performed this year?

AstraZeneca's stock was trading at $67.35 at the start of the year. Since then, AZN stock has increased by 27.0% and is now trading at $85.56. View the best growth stocks for 2024 here .

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) released its quarterly earnings results on Thursday, July, 25th. The company reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.01. AstraZeneca's revenue for the quarter was up 9.1% on a year-over-year basis.

When did AstraZeneca's stock split?

AstraZeneca's stock split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

2,350 employees have rated AstraZeneca Chief Executive Officer Pascal Soriot on Glassdoor.com . Pascal Soriot has an approval rating of 98% among the company's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. 87.0% of employees surveyed would recommend working at AstraZeneca to a friend.

Does AstraZeneca have any subsidiaries?

AstraZeneca subsidiaries include Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and others.

Who are AstraZeneca's major shareholders?

AstraZeneca's top institutional shareholders include Primecap Management Co. CA (1.37%), Dimensional Fund Advisors LP (0.14%), Envestnet Asset Management Inc. (0.11%) and Swedbank AB (0.09%). View institutional ownership trends .

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Moderna (MRNA) , Novavax (NVAX) , Regeneron Pharmaceuticals (REGN) , Albertsons Companies (ACI) , American Airlines Group (AAL) , Blue Apron (APRN) and BlackBerry (BB) .

Top-Rated StocksTop-Rated

NASDAQ:AZN

AstraZeneca (AZN) Stock Price, News & Analysis

$85.56

+0.43 (+0.51%)

(As of 08/21/2024 ET)

Compare

Today's Range: $84.67
▼
$85.61
50-Day Range: $76.67
▼
$85.56
52-Week Range: $60.47
▼
$85.65

Volume: 4.17 million shs
Average Volume: 5.33 million shs
Market Capitalization: $265.28 billion

P/E Ratio: 41.94
Dividend Yield: 1.15%
Price Target: $89.75

Get AstraZeneca alerts:

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.91 Rating Score
Upside/Downside: 4.9% Upside
$89.75 Price Target
Short Interest: Healthy
0.18% of Shares Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.81
Based on 17 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 15.61%
From $4.74 to $5.48 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.58 out of 5 stars

Medical Sector

309th out of 924 stocks

Pharmaceutical Preparations Industry

134th out of 426 stocks

2.5

Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
AstraZeneca has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about AstraZeneca's stock forecast and price target.

4.0

Short Interest

Percentage of Shares Shorted
0.18% of the outstanding shares of AstraZeneca have been sold short.
Short Interest Ratio / Days to Cover
AstraZeneca has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AstraZeneca has recently decreased by 1.55%, indicating that investor sentiment is improving.

2.5

Dividend Strength

Dividend Yield
AstraZeneca pays a meaningful dividend of 1.16%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 48.04%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 17.88% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.
Read more about AstraZeneca's dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AZN.

3.2

News and Social Media Coverage

News Sentiment
AstraZeneca has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for AstraZeneca this week, compared to 16 articles on an average week.
Search Interest
18 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
MarketBeat Follows
Only 17 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of -11% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 20.35% of the stock of AstraZeneca is held by institutions.
Read more about AstraZeneca's insider trading history.

3.1

Earnings and Valuation

Earnings Growth
Earnings for AstraZeneca are expected to grow by 15.61% in the coming year, from $4.74 to $5.48 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 41.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.90.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 41.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.84.
Price to Earnings Growth Ratio
AstraZeneca has a PEG Ratio of 1.36. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
AstraZeneca has a P/B Ratio of 6.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about AstraZeneca's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Preserve Gold

Trump is sounding the alarm

Europe is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?

Click here to get your complimentary retirement guide!

About AstraZeneca Stock (NASDAQ:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AZN Stock News Headlines

August 14, 2024 | marketbeat.com

Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs

AstraZeneca, T-Mobile US, and Intuitive Surgical are hitting all-time highs, driven by solid sector performance, robust earnings, and strategic advancements.

July 26, 2024 | marketbeat.com

AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance (AZN)

AstraZeneca beat earnings-per-share (EPS) estimates and raised guidance, but shares still fell. Investors should watch for developments around the drug Enhertu.

August 22, 2024 | DTI (Ad)

I never thought I would do this…

Now that the Fed has spoken, it’s sure to create a May Shockwave! Now's your best chance to trade this historic event using the method that has seen Doubles, Even Triples within just a few days! You see, while most folks will be paying $500… $1,000… or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options in a volatile market. You see, by entering on certain predetermined dates, we have been able to watch as these $0.25 Cent Trades doubled, even tripled in what feels like no time.

August 20 at 3:44 AM | msn.com

Up 38% from its 12-month low, how can AstraZeneca’s share price still look cheap?

August 19 at 12:43 PM | marketwatch.com

AstraZeneca rises Monday, still underperforms market

August 19 at 5:58 AM | markets.businessinsider.com

AZN: Enhertu Gets US Breakthrough Therapy Designation For HER2 Low/Ultralow Metastatic Breast Cancer

August 18, 2024 | finance.yahoo.com

AZN Aug 2024 66.000 put (AZN240823P00066000)

August 17, 2024 | finance.yahoo.com

AZN Aug 2024 76.000 call (AZN240823C00076000)

August 22, 2024 | DTI (Ad)

I never thought I would do this…

August 16, 2024 | msn.com

Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal

August 16, 2024 | marketwatch.com

AstraZeneca falls Friday, underperforms market

August 16, 2024 | msn.com

How Should You Play AstraZeneca (AZN) After Q2 Beat, View Raise?

August 16, 2024 | msn.com

AstraZeneca Imfinzi label expanded in U.S. for lung cancer

August 16, 2024 | markets.businessinsider.com

AstraZeneca's Imfinzi Gets US Approval For Resectable Early-stage Lung Cancer

August 15, 2024 | reuters.com

AstraZeneca's Imfinzi gets FDA priority review for type of lung cancer

August 14, 2024 | reuters.com

AstraZeneca gets $107 mln Pfizer verdict overturned in US cancer drug patent fight

August 14, 2024 | benzinga.com

AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding

August 14, 2024 | msn.com

AstraZeneca hits £200bn as its share price soars. Can I afford to miss out?

See More Headlines

Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/25/2024
Ex-Dividend for 9/9 Dividend: 8/09/2024
Today: 8/21/2024
Dividend Payable: 9/09/2024
Next Earnings (Estimated): 11/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceutical Products
Current Symbol: NASDAQ:AZN
CUSIP: N/A
CIK: 901832
Web: www.astrazeneca.com
Phone: 442037495000
Fax: 44-12-2335-2858
Employees: 89,900
Year Founded: 1999

Price Target and Rating

Average Stock Price Target: $89.75
High Stock Price Target: $97.00
Low Stock Price Target: $82.00
Potential Upside/Downside: +4.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.91
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.04
Trailing P/E Ratio: 41.94
Forward P/E Ratio: 18.05
P/E Growth: 1.36
Net Income: $5.96 billion
Net Margins: 13.11%
Pretax Margin: 15.77%
Return on Equity: 29.34%
Return on Assets: 11.15%

Debt

Debt-to-Equity Ratio: 0.69
Current Ratio: 0.89
Quick Ratio: 0.69

Sales & Book Value

Annual Sales: $49.13 billion
Price / Sales: 5.40
Cash Flow: $5.47 per share
Price / Cash Flow: 15.64
Book Value: $12.63 per share
Price / Book: 6.77

Miscellaneous

Outstanding Shares: 3,100,512,000
Free Float: N/A
Market Cap: $265.28 billion
Optionable: Optionable
Beta: 0.45

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Pascal Soriot D.V.M. (Age 65)
M.B.A., CEO & Executive Director
Comp: $5.76M
Dr. Aradhana Sarin M.D. (Age 50)
CFO & Executive Director
Comp: $3.18M
Ms. Pam P. Cheng (Age 54)
EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Mr. Andrew P. Barnett
Head of Investor Relations
Mr. Jeffrey Pott
CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Gonzalo Vina
Head of Global Media Relations
Dr. Menelas Nicolas Pangalos Ph.D. (Age 57)
Executive Vice-President
Dr. Ruud Dobber Ph.D.
Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D. (Age 58)
Ph.D., Executive Vice President of Oncology Research & Development
Mr. Leon Wang
Executive VP of International & China President

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AstraZeneca:

AstraZeneca's stock price has been showing a consistent upward trend, reaching a 12-month high of $80.86.
The company reported a strong quarterly revenue of $12.45 billion, surpassing analyst estimates.
Analysts predict AstraZeneca will post 4.02 earnings per share for the current fiscal year, indicating potential growth.
Recent analyst ratings have been positive, with several firms upgrading AstraZeneca to "buy" and "strong-buy" ratings.
AstraZeneca focuses on the discovery, development, manufacture, and commercialization of prescription medicines, a sector with high demand and growth potential.

Cons

Investors should be bearish about investing in AstraZeneca for these reasons:

AstraZeneca recently cut its dividend, which may impact income-seeking investors who rely on dividends for returns.
The company's dividend payout ratio is high at 94.61%, indicating a significant portion of earnings is being distributed as dividends.
While revenue was up 9.1% compared to the same quarter last year, it slightly missed analyst estimates, signaling potential challenges in meeting expectations.
The stock's price-to-earnings ratio of 38.30 may be considered high by some investors, suggesting the stock could be overvalued.
AstraZeneca's debt-to-equity ratio of 0.73 may raise concerns about the company's financial leverage and risk exposure.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, August 18, 2024. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AZN Stock Analysis - Frequently Asked Questions

How have AZN shares performed this year?: AstraZeneca's stock was trading at $67.35 at the start of the year. Since then, AZN stock has increased by 27.0% and is now trading at $85.56.
View the best growth stocks for 2024 here.
How were AstraZeneca's earnings last quarter?: AstraZeneca PLC (NASDAQ:AZN) released its quarterly earnings results on Thursday, July, 25th. The company reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.01. AstraZeneca's revenue for the quarter was up 9.1% on a year-over-year basis.
When did AstraZeneca's stock split?: AstraZeneca's stock split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.
What is Pascal Soriot's approval rating as AstraZeneca's CEO?: 2,350 employees have rated AstraZeneca Chief Executive Officer Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among the company's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. 87.0% of employees surveyed would recommend working at AstraZeneca to a friend.
Does AstraZeneca have any subsidiaries?: AstraZeneca subsidiaries include Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and others.
Who are AstraZeneca's major shareholders?: AstraZeneca's top institutional shareholders include Primecap Management Co. CA (1.37%), Dimensional Fund Advisors LP (0.14%), Envestnet Asset Management Inc. (0.11%) and Swedbank AB (0.09%).
View institutional ownership trends.
How do I buy shares of AstraZeneca?: Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
What other stocks do shareholders of AstraZeneca own?: Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Moderna (MRNA), Novavax (NVAX), Regeneron Pharmaceuticals (REGN), Albertsons Companies (ACI), American Airlines Group (AAL), Blue Apron (APRN) and BlackBerry (BB).

This page (NASDAQ:AZN) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

AstraZeneca (AZN) Stock Price, News & Analysis

AstraZeneca MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Dividend Coverage

Dividend Sustainability

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Earnings Growth Ratio

Price to Book Value per Share Ratio

About AstraZeneca Stock (NASDAQ:AZN)

AZN Stock Price History

AZN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

Pros

Cons

AZN Stock Analysis - Frequently Asked Questions

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Overall MarketRank^™